Welcome to ms-society.ie. By accessing http://www.ms-society.ie you are agreeing to comply with and be bound by the following terms and conditions of use.
The terms MS Society Ireland, Multiple Sclerosis Society of Ireland, MS Ireland, us or we refer to the owner of the website whose registered office is 80 Northumberland Road Dublin 2, Charity Number: 5365, Registration Number in Ireland: 296 573. The term ‘you’ refers to the user or viewer of our website.
Multiple Sclerosis of Ireland does not collect any personal information from visitors to its website other than non-personal data gathered in an aggregate form to get a better understanding of where our visitors come from and to help us better design and organise our website.
Data collected through the sign up of our newsletter, eNews, is used for the sole purpose of keeping subscribers up to date with developments in MS and MS Ireland. eNews is distributed once a month with other related emails distributed as the need arises. This information is not shared by any third party.
All emails sent by MS Ireland contain an unsubscribe function at the end of the email, should anyone wish to come off the mailing list.
All payments by credit card over the internet are processed through a secure server by Realex Payments on our behalf.
If you have any queries or questions about privacy and or security issues, please contact the web administrator.
This policy aims to inform MS Ireland website users that cookies are used on the website and how to go about opting out of cookie usage.
This policy applies to all visitors to the MS Ireland website
Cookies are small text files that are stored on your computer by the websites that you visit. Cookies enable some information about your visit to be recorded and enable websites to recognise a user anonymously based on the information stored in the cookie.
Cookies can be either ‘session’ or ‘persistent’. Session cookies are only stored for the duration of usage of the site and are deleted once the browser is closed. Persistent cookies can remain on your computer for longer specified periods.
There are two types of cookies: First-party cookies that are set by the site you are visiting and Third-party cookies which are set by other sites that have features embedded on the site you are visiting – such as advertisements or YouTube videos.
We use the following local cookies:
We also use Third-party cookies:
Cookies can be controlled through the settings on your browser, use the link specific to the browser you use to get information on how to do this.
There are a variety of free tools available that you can use to block cookies to help protect your online privacy. These are listed here for information purposes and do not represent an endorsement of any particular product.
The MS Ireland website is a free service for communication, self-expression and freedom of speech. We believe that our site increases the availability of information, encourages healthy debate and makes possible new connections between people.
We respect our users' ownership of and responsibility for the content they choose to share. It is our belief that censoring this content is contrary to a service that bases itself on freedom of expression.
In order to uphold these values, we need to curb abuses that threaten our ability to provide this service and the freedom of expression it encourages. As a result, there are some boundaries on the type of content that can be posted on our website. The boundaries we have defined are those that both comply with legal requirements and that serve to enhance the service as a whole.
We reserve the right to remove comments or refuse blog posts that include but are not limited to:
If behaviour falls outside of the accepted Guidelines, we will contact the individuals to ask them to refrain. If the issue persists individuals will be permanently banned from the page at our discretion.
This is a public page and as such any comments made you will be visible to other users. Please handle personal issues through personal contact.
MS Ireland assess each blog article for suitability and MS Ireland reserves the right to accept or decline the blog. Before using a blog MS Ireland may change the blog solely to correct errors or improve accessibility.
Issue 4 is out now! MS Research is a bi-annual research eZine. In each edition we will be sharing the latest updates from scientific and social MS research, from here in Ireland and internationally. In this issue Research prioritisation survey results Research event reports Causes of MS Biotin Physiotherapy Psychology Stem cells Myelin repair ECTRIMS And so much more…. Get in touch Contact Harriet Doig, Information, Advocacy and Research Officer: email firstname.lastname@example.org or call (01) 6781600
New international research published into treatment expectations of people with MS New international research finds that people living with MS prioritise slowing disease progression when considering treatment choices. People with MS want therapies that reduce the number of relapses they suffer and to achieve better control of symptoms like fatigue and pain. The TaP-MS survey, published on 8th December, gathered over 1,000 responses from people with MS in countries ranging from the US, Canada and Australia to Sweden, Germany, France and the UK. It found that as well as seeking to stop disease progression people with MS want more vitality and energy. A new University College London School of Pharmacy report (Greater Expectations: the Future Hopes of People with Multiple Sclerosis, also published last week) highlights the value of early diagnosis and universal access to medicines that people with MS and their doctors judge are most likely to benefit them. It stresses the need for personalised combinations of medical, pharmaceutical, nursing, psychological, social and economic support for people with MS and calls for regular auditing of care delivery standards. Greater Expectations argues that current economic evaluation methods can under-estimate the true value of better MS treatments. Fears about the affordability of high quality health and social care can also be exaggerated. The UCL School of Pharmacy report in addition points to the potential for MS prevention programmes aimed at reducing vitamin D deficiency related risks and cutting smoking and obesity rates amongst teenagers. However, providing disease modifying treatments and investing in ongoing biomedical research are central to further reducing MS related harm. Greater Expectations’ recommendations include: Governments throughout Europe should publicly commit to providing everyone with MS with the treatments that they, their neurologists and other professional advisers judge will offer them maximum benefit; There ought to be open access to reliable, up-to-date, figures on all forms of MS DMT use on a country by country and locality basis; Care funders should provide adequate facilities for the early identification of MS and monitoring treatment outcomes. This includes assuring good access to neurologists and to MRI scanning (Ireland has the lowest number of neurologists per heard in Europe and long waiting times to access MRI) as well as maintaining high quality disease registries; People with MS and organisations representing them have a vital part to play in raising MS care standards, preventing access inequalities and contributing to pharmaceutical literacy Download TaP-MS (Treatment Expectations and Priorities of People with MS) survey Download Greater Expectations: the Future Hopes of People with Multiple Sclerosis Further reading MS Ireland's Time to Act report on the importance of early diagnosis and treatment in MS MS Treatment Decisions - MS Ireland’s guide to making informed decisions about MS treatment options
Many people with multiple sclerosis experience falls, which can have significant consequences for the individual. The MS Research Team at the University of Limerick, led by Professor Susan Coote, have developed a falls prevention programme for people with multiple sclerosis and we would like to assess how suitable and effective the programme is. What do I have to do? The 'Better Balance' programme consists of 12 weeks of twice-weekly classes run by a chartered physiotherapist. The classes will consist of 45 minutes of exercises aimed at improving balance, strength and walking and 45 minutes of education on topics such as fear of falling, task analysis, getting up from the floor, what devices can assist you – these will include group discussions and problem solving. There will also be a home exercise programme provided to each participant. The classes will take place in Limerick and Galway and will be offered in the morning and/or evening depending on the preference of the individuals attending. Beginning in January, interested individuals will be asked to attend an assessment day where a chartered physiotherapist will test your strength, balance, walking and feelings about falls. We will then give you falls diaries to complete for two months. This is like a calendar where you will write down if you had a fall. After these two months, the classes will begin. When the 12 weeks of classes are finished you will again have your strength, balance, walking and feelings about falls assessed and complete another two months of falls diaries to see if the intervention has been successful. After completing the two months of falls diaries you will attend one last assessment with the researcher to assess your strength, balance, walking and feelings about falls. Who can participate? To be eligible to take part you must have multiple sclerosis, be over the age of 18 years, have experienced a fall in the last three months, and be able to walk for 10 metres with or without a walking aid (one stick or one crutch). Get in touch If you would be interested in taking part in this study or have any further questions about the study you can contact the researchers by calling Laura Comber on 086 0231335 or email Laura.email@example.com or Prof. Susan Coote on (061) 234278 or email firstname.lastname@example.org
Letter to Minister Simon Harris regarding ocrelizumab Today, (Monday, 11th December) MS Ireland have written to Minister for Health Simon Harris regarding new medication ocrelizumab, which is the first ever medication to be indicated for primary progressive MS. MS Ireland are asking the Minister to take action to ensure that this medication is made available to people with MS in Ireland as soon as possible. Further reading Download letter to Minister Simon Harris. Information about ocrelizumab Get in touch Questions or comments regarding this letter can be directed to Harriet Doig, Information, Advocacy and Research Officer – email@example.com
Irish life sciences company, Genomics Medicine Ireland (GMI) have announced an important scientific research study aimed at unlocking the mystery of the genetic and lifestyle factors that contribute to MS. Volunteers with MS currently being treated at St. Vincent’s University Hospital, Tallaght Hospital, Cork University Hospital or Altnagelvin Hospital in Derry are invited to participate in the study which aims to identify these factors in order to find better treatments, diagnoses and, ultimately, a cure for MS. GMI also hopes to rollout additional study sites around the country in future. MS Ireland welcomes this exciting new study as an opportunity to further understand the causes and mechanisms of MS, which will hopefully lead to better management and treatment of the disease in the future. Further information on the study is available in the third issue of our research eZine, Interested volunteers should speak with their clinical team at one of the current research sites for more information. Further information: Read the full press release from Genomics Medicine Ireland RTE News
06:00 - 23:00
11:00 - 12:00
11:00 - 13:00
11:15 - 12:15